Clinical Trial Details
| Trial ID: | L2713 |
| Source ID: | NCT01719640 |
| Associated Drug: | Infusion Of Mscs |
| Title: | MSC and MC in Type 2 Diabetes Mellitus |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: infusion of MSCs|DRUG: infusion MCs|DRUG: insulin |
| Outcome Measures: | Primary: macrovascular complications, 8 years|microvascular complications, 8 years | Secondary: DPN, diabetes peripheral neuropathy, 8 years|MI, myocardial infarction, 8 years|angina, angina, 8 years|stroke, stroke, 8 years|amputation, amputation, 8 years|DN, diabetes nephropathy, 8 years|DRP, diabetes retinopathy, 8 years|pro-DRP, proliferative diabetes retinopathy, 8 years|C-peptide AUC, C-peptide area under the curve, 1y|insulin AUC, insulin area under the curve, 1y|HbA1c, glycated hemoglobin, 1y|FBG, fasting hemoglucose, 1y|insuline dose, exogenous insulin requirements, 1y|fasting C-p, fasting c-peptide, 1y|The incidence and severity of adverse events related to the stem cell infusion procedure, 8y |
| Sponsor/Collaborators: | Sponsor: Fuzhou General Hospital |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1|PHASE2 |
| Enrollment: | 22 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2011-01 |
| Completion Date: | 2020-01 |
| Results First Posted: | |
| Last Update Posted: | 2023-01-12 |
| Locations: | Fuzhou General Hospital, Xiamen Univ, Fuzhou, Fujian, 350025, China |
| URL: | https://clinicaltrials.gov/show/NCT01719640 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|